The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Specifically tailored to workflows for nuclear medicine and molecular imaging, the InterView™ Fusion (Mediso) and InterView XP (Mediso) multimodality (PET/SPECT/MRI/CT) image processing and reporting software have garnered 510(k) clearance from the Food and Drug Administration (FDA).
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including cardiac, bone, thyroid, liver, and lung imaging, according to Mediso.
The company said the InterView software also features a variety of modules that facilitate automated lesion detection and segmentation as well as image denoising.
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including bone imaging. (Images courtesy of Mediso.)
Mediso added that the vendor independent software can be utilized on stand-alone workstations or be incorporated seamlessly into physical or virtual servers of hospital information systems.
“The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application, and they demonstrate our continuous commitment to the molecular imaging market,” noted Istvan Bagamery, the founder and CEO of Mediso.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).